All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ripretinib
Therapeutic Area: Oncology Product Name: Qinlock
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Deciphera Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 06, 2020
Details:
Specialised Therapeutics Asia (STA) to make QINLOCK® (ripretinib) available to appropriate patients in Australia, New Zealand, Singapore, Malaysia and Brunei following exclusive distribution agreement.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Neratinib Maleate
Therapeutic Area: Oncology Product Name: Nerlynx
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2020
Details:
NERLYNX significantly reduce the ongoing risk of recurrence in HER2+ early breast cancer patients with the greatest benefit seen in women who are also HR+and who commence therapy within 12 months of completing trastuzumab-based therapy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tisagenlecleucel
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 28, 2020
Details:
Novartis has entered into an agreement with Cell Therapies to manufacture Kymriah at their production facility within the Peter MacCallum Cancer Centre in Melbourne.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
